Janney MS, Subramaniyan R, Dabas R, Lal S, Das NM, Godara SK
IGF-1 DESs short half-life makes it ideal for: Targeted injection into desired muscle groups Minimizing risk of systemic IGF-1 overexposure (which can lead to unwanted growth in non-target tissues) How It Differs From IGF-1 LR3 The DES(1-3) form of IGF-1 demonstrates higher potency for local anabolic effects due to enhanced receptor affinity and reduced binding to IGF binding proteins. Philippou et al., Cell Communication and Signaling Clinical & Performance Use Today While IGF-1 DES remains a research peptide and is not FDA-approved for human therapeutic use, it is widely used off-label by: Bodybuilders targeting lagging muscle groups (arms, calves, chest) Strength athletes recovering from tendon and ligament injuries Physique competitors preparing for contests Anti-aging practitioners promoting collagen synthesis and joint health It is also commonly stacked with: GH secretagogues (MK-677, CJC-1295, Ipamorelin) Recovery peptides (BPC-157 for Recovery, TB500) for comprehensive muscle growth + tissue repair protocols
Williams JR, Carter CS, Insel T (1992)
The company began a dedicated development program, completing the STEP clinical trial series between 2019 and 2020
3000mah battery x 30C = 90,000mA = 90 Amps maximum continuous output So it's interesting to see from above that increase Capacity has a similar effect to sticking with the same size and increase C-rating
Building better biomarkers: brain models in translational neuroimaging
